Tirzema 2.5mg Pre-Filled Syringe

✔️ Common Side Effects:

Gastrointestinal Issues:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Abdominal pain
• Indigestion (Dyspepsia)

Injection Site Reactions:

• Pain, swelling, or redness at the injection site.

Other Symptoms:

• Fatigue
• Hypersensitivity (allergic reactions)
• Burping
• Hair loss
• Gastro-esophageal reflux disease (GERD)

✔️ Indications:

Tirzepatide offers an effective solution for managing blood sugar and weight in people with type 2 diabetes mellitus, although like any medication

✔️ Quick Suggestions:

• Take the injection on the same day each week for consistency. Use a reminder to help you stay on track.
• Rotate the injection sites (abdomen, thigh, upper arm) to reduce irritation and improve absorption.
• Contact your doctor immediately if you experience severe abdominal pain or throat swelling.
• Take other oral medications an hour before the injection to avoid delayed absorption.
• Combine the treatment with a healthy diet and regular physical activity for best results.

✔️ Preparation and Administration:

• The needle cover of the pre-filled syringe contains dry natural rubber (latex), which may cause allergic reactions.
• Do not freeze the medication or use Tirzepatide if it has been frozen.
• Protect the pre-filled syringes from light and store them as per instructions.
• Before use, visually inspect the pre-filled syringe for particulate matter or discoloration. Do not use if the syringe has any visible issues.
• Handle the syringe with care; if dropped on a hard surface, it should not be used.
  Administer Tirzepatide subcutaneously once a week at any time of day, with or without meals.
• It can be injected into the abdomen, thigh, or upper arm, rotating injection sites with each dose.
• If using insulin, administer it separately from Tirzepatide and avoid mixing. It is okay to inject both in the same body area, but they should not be adjacent to each other.

✔️ Tirzepatide Dosing Instructions:

Starting Dosage: The recommended initial dosage of Tirzepatide is 2.5 mg injected subcutaneously once weekly. This starting dose is for treatment initiation and is not intended for immediate glycemic control.

Dosage Escalation:

• After 4 weeks, increase the dosage to 5 mg once weekly.
• For additional glycemic control, further dosage increases can be made in 2.5 mg increments after at least 4 weeks on the current dose.
• The maximum dosage is 15 mg once weekly.

Missed Dose: If a dose is missed, patients should administer it as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and resume the regular weekly schedule on the next due date.

Changing Weekly Administration Day: The day of weekly administration can be changed if necessary, as long as there is at least 72 hours (3 days) between doses.

✔️ Interactions:

• When using Tirzepatide with insulin secretagogues (e.g., sulfonylureas) or insulin, the dose of these medications may need to be reduced to lower the risk of hypoglycemia.
• Tirzepatide may delay gastric emptying, which can affect the absorption of oral medications. It is important to monitor oral medications that depend on specific blood concentrations or those with a narrow therapeutic index (e.g., warfarin).
• Oral contraceptives: Patients using oral hormonal contraceptives should switch to a non-oral contraceptive or add a barrier method for 4 weeks after initiation and after each dose escalation.

✔️ Contraindications:

• Tirzepatide should not be used in patients who have a known hypersensitivity to tirzepatide or any of its ingredients.
• It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or those with multiple endocrine neoplasia syndrome type 2 (MEN 2).

✔️ Pregnancy and Lactation:

• Tirzepatide should only be used during pregnancy if the benefits outweigh the risks to the fetus.
• It is important to weigh the benefits of breastfeeding against potential risks from Tirzepatide or the mother's condition.

✔️ Precautions:

• Monitor patients for signs of thyroid tumors, particularly medullary thyroid carcinoma (MTC), after starting treatment.
• Pancreatitis: Watch for symptoms of pancreatitis. Discontinue if suspected and manage appropriately.
• Hypoglycemia risk: May be reduced by adjusting doses of insulin or sulfonylureas.
• Renal function: Monitor closely in patients with renal impairment.
• Retinopathy: Watch for worsening in patients with a history of diabetic retinopathy.

✔️ Storage:

• Keep out of the reach of children.
• Store between 2°C to 8°C (refrigerated) and do not freeze.
• Protect from light and do not use if the medication has been frozen.